SPPL3 and neoplasm: We also observed significant enrichment of sgRNAs targeting SPPL3, which has recently been shown to impede antibody and receptor interactions with HLA class I glycoproteins.30 The results suggest that loss of SPPL3 might also be a novel mechanism for tumor cells to escape from CAR T cells (Supplemental Table 1).